Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

  1. Rastogi, P.
  2. O'shaughnessy, J.
  3. Martin, M.
  4. Boyle, F.
  5. Cortes, J.
  6. Rugo, H.S.
  7. Goetz, M.P.
  8. Hamilton, E.P.
  9. Huang, C.-S.
  10. Senkus, E.
  11. Tryakin, A.
  12. Cicin, I.
  13. Testa, L.
  14. Neven, P.
  15. Huober, J.
  16. Shao, Z.
  17. Wei, R.
  18. André, V.
  19. Munoz, M.
  20. San Antonio, B.
  21. Shahir, A.
  22. Harbeck, N.
  23. Johnston, S.
Journal:
Journal of Clinical Oncology

ISSN: 1527-7755 0732-183X

Year of publication: 2024

Volume: 42

Issue: 9

Pages: 987-993

Type: Article

DOI: 10.1200/JCO.23.01994 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals